Search the Newsreel

JUVÉDERM marks 20 years since FDA approval with buy-one-get-one $75 cards

AbbVie's Allergan Aesthetics announced the fourth annual JUVÉDERM® Day will occur on August 19, 2026, coinciding with the 20th anniversary of the brand's first U.S. FDA dermal filler approval. Allē members can access a buy-one-get-one $75 JUVÉDERM® gift card promotion and double Allē points …

JUVÉDERM® Day Returns to U.S. on August 19

Allergan Aesthetics celebrates fourth annual JUVÉDERM®Day with buy-one-get-one (BOGO) gift cards and double points for Allē Members This summer marks the 20th anniversary of the brand's first U.S. Food and Drug Administration (FDA) dermal filler approval Join Allē today to take advantage of limited …

New Century Logistics (BVI) Ltd (NCEW) Financial Health: Profitability & Balance Sheet Analysis

This article provides a detailed financial analysis of New Century Logistics (BVI) Ltd (NCEW), presenting its profitability and balance sheet data. It includes key financial indicators from the FY2025 earnings report, such as revenue, EPS, various assets and liabilities, and profitability ratios. The analysis …

AbbVie, Inc. CDR (CAD Hedged) Revenue Breakdown – NEO:ABBV

This article provides a revenue breakdown for AbbVie, Inc. CDR (CAD Hedged) under the ticker NEO:ABBV, sourced from TradingView. It highlights that the United States was the primary contributor to AbbVie's revenue, bringing in 65.12 billion CAD last year and 58.95 billion CAD the …

AbbVie, Inc. Shs Unsponsored Brazilian Depository Receipt Repr 0.0625 Sh Revenue Breakdown – BMFBOVESPA:ABBV34 – TradingView

This article provides a revenue breakdown for AbbVie, Inc. Brazilian Depository Receipts (ABBV34) traded on the BMFBOVESPA, highlighting that the United States is the largest contributor to its revenue. The financial data indicates significant revenue in BRL during the last two years.

The Real Price of AbbVie Stock Is Cheaper Than You Think

AbbVie (ABBV) stock appears expensive at first glance with a high price-to-earnings multiple, but a deeper analysis reveals it's cheaper than it seems. When factoring in expected earnings by 2027, the stock's valuation drops significantly due to anticipated growth. This "forward discount" is driven …

BUREAU VERITAS - 2026 Half-Year Financial Report

BUREAU VERITAS PRESS RELEASE Courbevoie – July 29, 2026 Bureau Veritas announces the publication of its half-year financial report for the six months ended 30 June 2026 Bureau Veritas announces the public release and the filing with the Autorité des marchés financiers of its …

AbbVie (ABBV) Stock May Be Mispriced On Its 172% Run

AbbVie (ABBV) has seen strong returns over five years (172%), but its current valuation presents a mixed picture. While a Discounted Cash Flow (DCF) analysis suggests the stock is undervalued by 43.4% at an intrinsic value of $465 per share, its Price-to-Earnings (P/E) ratio …

Bureau Veritas Aktie: Starker Kursanstieg nach überzeugenden Zahlen und Prognoseerhöhung

AbbVie wins EU clearance for Rinvoq as first systemic treatment for non-segmental vitiligo (ABBV:NYSE)

AbbVie announced that the European Commission has approved Rinvoq for the treatment of adult and adolescent patients aged 12 years and older with non-segmental vitiligo, who are candidates for systemic therapy. This approval marks Rinvoq as the first systemic treatment of its kind for …

Bureau Veritas : inspection réussie, ambitions relevées

Bureau Veritas prend plus de 9% en Bourse après avoir relevé sa prévision de croissance pour l'année

AbbVie Announces European Commission Approval of RINVOQ® (upadacitinib) for the Treatment of Adults and Adolescents with Non-Segmental Vitiligo

RINVOQ is the first and only systemic medication approved in the European Union to treat adult and adolescent patients with non-segmental vitiligo (NSV) The approval is supported by data from the Phase 3 Viti-Up clinical program, which showed that RINVOQ achieved statistically significant total …

Bureau Veritas relève ses objectifs après un bon premier semestre

Bureau Veritas SA legt Ergebnisse für das Halbjahr zum 30. Juni 2026 vor

Pourquoi l’action Bureau Veritas bondit-elle fortement aujourd’hui ?

EU Approves AbbVie's RINVOQ After Trials Show Complete Scalp Hair Regrowth

The European Commission has approved AbbVie's RINVOQ (upadacitinib) for treating severe alopecia areata in adults and adolescents aged 12 and older. This approval is supported by Phase 3 trials where RINVOQ demonstrated significant scalp hair regrowth, including complete regrowth in some patients, at both …

Bureau Veritas se montre plus confiant pour 2026 après un solide T2

Bureau Veritas hebt Prognose für organisches Umsatzwachstum im GJ26 an

Bureau Veritas : Engagements tenus avec une accélération séquentielle de la croissance organique au T2 et une amélioration continue des marges

Bureau Veritas: Delivering on Our Commitments With Higher Sequential Organic Growth in Q2 and Continuous Margin Improvements

COURBEVOIE, France, July 29, 2026--(BUSINESS WIRE)--Bureau Veritas (BOURSE:BVI): H1 2026 key figures1 › Revenue of EUR 3,258.4 million in H1 2026, up 2.1% year-on-year and up 5.0% organically (with a sequential improvement in Q2 2026 at 5.5% organic growth), › Adjusted operating profit of …

AbbVie Announces Availability of ELAHERE® (mirvetuximab soravtansine) in Singapore for the Treatment of Platinum-Resistant Ovarian Cancer

AbbVie has announced the availability of ELAHERE (mirvetuximab soravtansine) in Singapore for treating platinum-resistant ovarian cancer. This antibody-drug conjugate (ADC) is the first and only one approved for patients with FRα-positive high-grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer who have undergone …

AbbVie Inc (ABBV) director adds stock-equivalent units after 25.5% 12-week rise

The insider acquisition lands with the biopharma stock still in an active weekly trend, though latest volume ran below its 13-week average.

Botox Maker Tops Buy Point, But Here Comes The Earnings Report

AbbVie closed above the 230.47 buy point from a cup-with-handle base on June 23 and has climbed 15% from there. The previous day, the stock jumped more than 6% after AbbVie announced it agreed to acquire Apogee Therapeutics. The $10.9 billion deal would strengthen …

Should You Buy, Hold or Sell ABBV Stock Ahead of Q2 Earnings?

AbbVie ABBV is set to report second-quarter 2026 earnings on July 31, before the opening bell. The Zacks Consensus Estimate for the to-be-reported quarter's sales is pinned at $16.81 billion, while earnings per share (EPS) are estimated at $3.66. Both metrics indicate an increase …

AbbVie Inc. stock outperforms competitors on strong trading day

AbbVie Inc. (ABBV) stock advanced 2.45% to $263.20 on Tuesday, outperforming the S&P 500 Index and the Dow Jones Industrial Average. The company also reached a new 52-week high, exceeding its previous peak from the day before.

AbbVie Inc Stock (ABBV) Moved Up by 3.35% on Jul 28: A Full Analysis

AbbVie Inc (ABBV) saw its stock rise by 3.35% on July 28, outperforming the Pharmaceuticals & Medical Research sector. This strong performance was attributed to robust second-quarter earnings, significant growth in its immunology drugs Skyrizi and Rinvoq, and positive late-stage clinical trial data in …

Barclays Adjusts AbbVie PT to $300 From $275, Maintains Overweight Rating

Barclays has increased its price target for AbbVie (ABBV) to $300 from $275, while reiterating an Overweight rating on the stock. The adjustment reflects an updated outlook from the analytical firm regarding the pharmaceutical company's future performance. AbbVie specializes in therapeutic drug research and …

New Century Logistics (BVI) Limited Revenue Breakdown – NASDAQ:NCEW

Sarepta taps AbbVie, Tessera vet Severino to write Duchenne firm's next chapter

Sarepta Therapeutics has appointed Michael Severino, former vice chairman at AbbVie and CEO of Tessera Therapeutics, as its new chief executive, effective Tuesday. Severino replaces Doug Ingram, who is retiring due to family health issues. Severino will face the challenge of navigating commercial realities …

Sarepta, in search of a turnaround, taps ex-AbbVie exec Severino as CEO

Sarepta Therapeutics has appointed Michael Severino, an executive with experience at AbbVie and Amgen and most recently Tessera Therapeutics, as its new CEO, effective July 28. Severino faces the challenge of turning around Sarepta's fortunes, as the company has lost significant market value over …

Sarepta names former AbbVie R&D exec Michael Severino as next CEO

Sarepta Therapeutics has appointed Michael Severino, formerly of Tessera Therapeutics and AbbVie, as its new CEO, succeeding Doug Ingram. Severino takes the helm at a critical juncture as Sarepta awaits two key FDA decisions for its Duchenne muscular dystrophy drugs, Amondys 45 and Vyondys …

AbbVie stock hits all-time high of 261.71 USD

AbbVie Inc. (ABBV) stock has reached a new all-time high of $261.71, reflecting a 40.53% total return over the past year. Despite being considered slightly overvalued by InvestingPro analysis, the company demonstrates strong financial health with 9.5% revenue growth. Upcoming earnings on July 31st …

Is AbbVie Stock a Buy After Its $10.9 Billion Apogee Bet

AbbVie (ABBV) recently acquired Apogee Therapeutics for $10.9 billion, a move that is expected to dilute adjusted EPS until 2032 but aims for a "mega blockbuster" drug, zumilokibart, targeting over $10 billion in peak sales. Despite the near-term dilution, AbbVie stock has largely recovered …

Sarepta names former Abbvie president as CEO as Ingram retires

Sarepta Therapeutics has appointed Michael Severino, former Tessera Therapeutics CEO and a longtime AbbVie executive, as its new chief executive, effective July 28. Severino will succeed Doug Ingram, who is stepping down after leading Sarepta since 2017 but will remain in an advisory role …

New Century Logistics (BVI) Ltd (NCEW) Cash Flow

This article provides an overview of New Century Logistics (BVI) Ltd's (NCEW) cash flow statements, including operating, investing, and financing cash flows, along with definitions for each. It highlights key financial figures for the company, such as a -3.42M operating cash flow in fiscal …